Plaque Psoriasis
📧 Sign up to get email alerts when something new happens for Plaque Psoriasis.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2013-11-07FDA Approved: TACLONEX — Supplemental Application (LEO Pharma Inc.)
The FDA approved a supplemental application for TACLONEX, the fixed-dose combination of calcipotriene and betamethasone dipropionate, submit…
-
FDA approval · 2013-06-28FDA Approved: TACLONEX — Supplemental Application (LEO Pharma Inc.)
FDA approved a supplemental application for Taclonex (calcipotriene and betamethone dipropionate) from LEO Pharma Inc., resulting in updated…
-
FDA approval · 2013-04-29FDA Approved: USTEKINUMAB — Supplemental Application (Janssen Biotech, Inc.)
FDA approved a supplemental application for ustekinumab from Janssen Biotech, expanding its labeling and indications.
-
FDA approval · 2013-04-25FDA Approved: CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE — Supplemental Application (Prasco Laboratories)
FDA approves a supplemental application for CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE submitted by Prasco Laboratories.
-
FDA approval · 2013-04-24FDA Approved: HUMIRA — Supplemental Application (Cordavis Limited)
FDA approved a supplemental application for Humira (adalimumab) submitted by Cordavis Limited.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2013-04-11FDA Approved: DESOXIMETASONE — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA approved Sun Pharmaceutical's desoximetasone topical product under an Original Application for the treatment of inflammatory and pruriti…
-
FDA approval · 2013-02-07FDA Approved: SANDIMMUNE — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for SANDIMMUNE (cyclosporine) from Novartis, indicating updated labeling or expanded use via a suppl…
-
FDA approval · 2013-01-25FDA Approved: USTEKINUMAB — Supplemental Application (Janssen Biotech, Inc.)
FDA approves a supplemental application for ustekinumab (Stelara) from Janssen Biotech, Inc.
-
FDA approval · 2012-12-10FDA Approved: ENBREL — Supplemental Application (Immunex Corporation)
The FDA approved a supplemental application for ENBREL (etanercept) submitted by Immunex Corporation.
-
FDA approval · 2012-12-04FDA Approved: ENBREL — Supplemental Application (Immunex Corporation)
FDA approved a supplemental application for Enbrel (etanercept) submitted by Immunex Corporation.
-
FDA approval · 2012-09-28FDA Approved: HUMIRA — Supplemental Application (Cordavis Limited)
The FDA approved a supplemental application for HUMIRA (adalimumab) submitted by Cordavis Limited.
-
FDA approval · 2012-09-27FDA Approved: CALCIPOTRIENE — Supplemental Application (Mayne Pharma)
The FDA approved a supplemental application for CALCIPOTRIENE submitted by Mayne Pharma.
-
FDA approval · 2012-05-24FDA Approved: HUMIRA — Supplemental Application (Cordavis Limited)
FDA approved a supplemental application for HUMIRA (adalimumab) submitted by Cordavis Limited.
-
FDA approval · 2012-05-11FDA Approved: TAZAROTENE — Original Application (Mayne Pharma Inc.)
The FDA approved Mayne Pharma's original application for tazarotene, a topical retinoid, for dermatologic use.
-
FDA approval · 2012-05-02FDA Approved: USTEKINUMAB — Supplemental Application (Janssen Biotech, Inc.)
FDA approved a supplemental application for ustekinumab (Stelara) from Janssen Biotech, Inc., resulting in a labeling change/addition.
-
FDA approval · 2011-12-26FDA Approved: HUMIRA — Supplemental Application (Cordavis Limited)
The FDA has approved a supplemental application for Humira (adalimumab) submitted by Cordavis Limited.
-
FDA approval · 2011-12-13FDA Approved: HUMIRA — Supplemental Application (Cordavis Limited)
FDA approved a supplemental application for HUMIRA (adalimumab) filed by Cordavis Limited.
-
FDA approval · 2011-02-25FDA Approved: TAZORAC — Supplemental Application (Almirall, LLC)
The FDA approved a supplemental application for TAZORAC (tazarotene) from Almirall, LLC.
-
FDA approval · 2011-02-17FDA Approved: INFLIXIMAB — Supplemental Application (Janssen Biotech, Inc.)
The FDA approved a supplemental application for infliximab from Janssen Biotech, Inc., signaling a labeling update or expansion of its appro…
-
FDA approval · 2010-12-28FDA Approved: INFLIXIMAB — Supplemental Application (Janssen Biotech, Inc.)
FDA approved Janssen Biotech, Inc.'s supplemental application for infliximab. The approval updates the product's labeling and indications as…
-
FDA approval · 2010-07-29FDA Approved: HUMIRA — Supplemental Application (Cordavis Limited)
The FDA has approved a supplemental application for HUMIRA (adalimumab) filed by Cordavis Limited.
-
FDA approval · 2010-07-29FDA Approved: CIMZIA — Supplemental Application (UCB, Inc.)
The FDA approved a supplemental application for CIMZIA (certolizumab pegol) submitted by UCB, Inc., resulting in an approved amendment to it…
-
FDA approval · 2010-06-03FDA Approved: ENBREL — Supplemental Application (Immunex Corporation)
The FDA approved a supplemental application for Enbrel (etanercept) submitted by Immunex Corporation.
-
FDA approval · 2010-03-30FDA Approved: CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE — Supplemental Application (Prasco Laboratories)
FDA approved a supplemental application by Prasco Laboratories to market a Calcipotriene and Betamethrone Dipropionate product for treating …
-
FDA approval · 2010-03-24FDA Approved: CALCIPOTRIENE — Original Application (Glenmark Pharmaceuticals Inc., USA)
FDA approved Glenmark's CALCIPOTRIENE original ANDA, granting a generic version of the topical psoriasis treatment.